Lbl-034, a Highly Differentiated T-Cell Engaging Bispecific Antibody Targeting GPRC5D for the Treatment of Relapsed or Refractory Multiple Myeloma

被引：3
|
作者：
Wang, Baohui [1 ]
Huang, Xiao [1 ]
Sun, Jianming [1 ]
Qin, Yurong [1 ]
Shang, Hongyan [1 ]
Li, Tingting [1 ]
Wu, Guojin [1 ]
Chen, Min [1 ]
Wang, Hailin [1 ]
Zhang, Peng [1 ]
Jiang, Duqing [1 ]
Liu, Tongjun [1 ]
Ye, Mi [1 ]
Cai, Shengli [1 ]
Lai, Shoupeng [1 ]
Kang, Xiaoqiang [1 ]
Ling, Hong [1 ]
机构：
[1] Nanjing Leads Biolabs Co Ltd, Nanjing, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-181395
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Targeting GPRC5D With Talquetamab: A New Frontier in Bispecific Antibody Therapy for Relapsed/Refractory Multiple Myeloma
    Shaver, Jacob
    Horton, Daniel
    Halford, Zachery
    ANNALS OF PHARMACOTHERAPY, 2025, 59 (04) : 350 - 363
  • [2] Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
    Merz, Maximilian
    Dima, Danai
    Hashmi, Hamza
    Ahmed, Nausheen
    Stoelzel, Friedrich
    Holderried, Tobias A. W.
    Fenk, Roland
    Mueller, Fabian
    Tovar, Natalia
    Oliver-Caldes, Aina
    Rathje, Kristin
    Davis, James A.
    Fandrei, David
    Vucinic, Vladan
    Kharboutli, Soraya
    Baermann, Ben-Niklas
    Ayuk, Francis
    Platzbecker, Uwe
    Albici, Anca-Maria
    Schub, Nathalie
    Schmitz, Friederike
    Shune, Leyla
    Khouri, Jack
    Anwer, Faiz
    Raza, Shahzad
    Mcguirk, Joseph
    Mahmoudjafari, Zahra
    Green, Kimberly
    Khandanpour, Cyrus
    Teichert, Marcel
    Jeker, Barbara
    Hoffmann, Michele
    Kroeger, Nicolaus
    von Tresckow, Bastian
    de Larrea, Carlos Fernandez
    Pabst, Thomas
    Abdallah, Al-Ola
    Gagelmann, Nico
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [3] Application of GPRC5D Targeting Therapy in Relapsed Refractory Multiple Myeloma
    Yan, Sijia
    Ming, Xi
    Zheng, Rubing
    Zhu, Xiaojian
    Xiao, Yi
    CANCER MEDICINE, 2025, 14 (06):
  • [4] Changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody therapy in patients with relapsed refractory multiple myeloma (RRMM).
    Janardan, Abhishek
    Lindsay, Hammons
    Szabo, Aniko
    Bhatlapenumarthi, Vineel
    Annyapu, Evanka
    Dhakal, Binod
    Narra, Ravi Kishore
    Al Hadidi, Samer
    Radhakrishnan, Sabarinath Venniyil
    Bhutani, Divaya
    Thanendrarajan, Sharmilan
    Siegfried, Janz
    Zangari, Maurizio
    Lentzsch, Suzanne
    van Rhee, Frits
    D'Souza, Anita
    Chakraborty, Rajshekhar
    Schinke, Carolina D.
    Mohan, Meera
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
    Hammons, Lindsay
    Szabo, Aniko
    Janardan, Abhishek
    Bhatlapenumarthi, Vineel
    Annyapu, Evanka
    Dhakal, Binod
    Al Hadidi, Samer
    Radhakrishnan, Sabarinath Venniyil
    Narra, Ravi
    Bhutani, Divaya
    Thanendrarajan, Sharmilan
    Janz, Siegfried
    Zangari, Maurizio
    Lentzsch, Suzanne
    van Rhee, Frits
    Crescencio, Juan Carlos Rico
    D'Souza, Anita
    Chakraborty, Rajshekhar
    Mohan, Meera
    Schinke, Carolina
    HAEMATOLOGICA, 2024, 109 (03) : 906 - 914
  • [6] Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab
    A. M. G. A. Laheij
    N. W. C. J. van de Donk
    Supportive Care in Cancer, 2024, 32
  • [7] An Uniquely Designed Asymmetric Bispecific Antibody Against GPRC5D and CD3 (LBL-034) in Patients with Relapsed/Refractory Multiple Myeloma: A Phase I/II, First in Human, Open-Label, Multicenter, Dose Escalation/Expansion Study
    Qin, Ling
    Zhong, Yuping
    Huang, Dongping
    Xie, Haitang
    Du, Xin
    Liao, Aijun
    Zhang, Hongli
    Cai, Shengli
    Lu, Jin
    BLOOD, 2024, 144 : 4736 - 4737
  • [8] Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab
    Laheij, A. M. G. A.
    van de Donk, N. W. C. J.
    SUPPORTIVE CARE IN CANCER, 2024, 32 (01)
  • [9] Safety and Efficacy of GPRC5D CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients
    Li, Shiqi
    Yuan, Zhongtao
    Liu, Lin
    Li, Yu
    Luo, Le
    Chen, Yingnian
    Zhang, Lihua
    Li, Guangchao
    Luo, Min
    Zeng, Kaikai
    Ma, Donghui
    Wang Sanbin, Sr.
    BLOOD, 2023, 142
  • [10] Real World Outcomes with Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody: A Single Center Experience for Relapsed/ Refractory Multiple Myeloma (RRMM)
    Gill, Sarvarinder Kaur
    Fleming, Erika
    Gebre, Helen
    Bangolo, Ayrton, I
    Siegel, David S.
    Vesole, David H.
    Biran, Noa
    Parmar, Harsh
    Phull, Pooja
    BLOOD, 2024, 144 : 7047 - 7048
12345